N/A N=20 An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders
Encopresis · Autistic Disorder
Primary: Percent Continent — 0; 0; 6; 0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=117 Treatment of Encopresis in Children With Autism Spectrum Disorders
Encopresis · Autism Spectrum Disorder
Primary: Percentage of Continent Bowel Movements — 27.33; 16.99; 20.70; 55.50 percentage of bowel movements
N/A N=120 Sacral Nerve Stimulation Therapy for the Treatment of Chronic Fecal Incontinence
Fecal Incontinence
Primary: Proportion of Subjects With at Least 50% Reduction in Number of Incontinent Episodes Per Week — 0.73 proportion of subjects — p=<0.0001
Phase 2 N=44 A Placebo-Controlled Study of Clonidine for Fecal Incontinence.
Fecal Incontinence
Primary: Mean Fecal Incontinence and Constipation Assessment (FICA) Score — 8.1; 9.1; 6.5; 7.6 units on a scale
N/A N=124 Effects of an Anal Insert Device in Fecal Incontinence
Fecal Incontinence
Primary: Primary Effectiveness Endpoint — 75.9 percentage of treatment responders
N/A N=20 The Use of an "Anal-Tape" in Patients With Fecal Incontinence
Fecal Incontinence
Primary: Any Improvment in the Fecal Incontince Quality of Life Scale (FIQoLs) — 2.8; 3.3; 1.9; 2.5 score on a scale
N/A N=12 Proof of Concept: "Bottom's Up" Seat to Treat Constipation
Constipation Aggravated · Pelvic Floor; Incompetency
Primary: Adverse Events — 0 Participants
Phase 3 N=56 A Study of Colesevelam in Fecal Incontinence
Fecal Incontinence · Bile Acid Malabsorption
Primary: Number of Participants to Report a 50% or Greater Reduction in Weekly Fecal Incontinence (FI) Episodes — 17; 13 Participants — p=0.85
N/A N=200 Fecal Incontinence Treatment (FIT) Study
Fecal Incontinence · Bowel Incontinence
Primary: Treatment Response Defined as a 75% or Greater Change in Number of Average Weekly FI Episodes at Month 3 Follow-Up Compared to Baseline — 29; 28 Participants
N/A N=4 Toilet Training Toddlers and Preschoolers
Incontinence · Enuresis
Primary: Change in the Mean Number of Accidents Across Children — -1.3 Accidents
Phase 4 N=5 A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children
Fecal Incontinence · Neurogenic Bowel
Primary: Fecal Soiling - Number of Participants That Gained and Maintained Continence on Each Flushing Regimen — 1; 4 Participants
Phase 3 N=300 Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)
Fecal Incontinence
Primary: Change From Baseline St. Mark's (Vaizey) Score — -5.5; -4.4; -4.5; -3.4 units on a scale — p=0.092
N/A N=102 Maintenance Treatment for Children With Constipation
Constipation
Primary: Treatment Recovery — 33; 19 participants — p=0.024
Phase 3 N=80 Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence
Fecal Incontinence
Primary: 7-day Bowel Diary, Number of Fecal Incontinence Episodes — 7.3; 7.9; 4.8; 4.1 Fecal incontinence episodes
Phase 3 N=215 Prucalopride in Pediatric Subjects With Functional Constipation
Functional Constipation
Primary: Percent of Responders in the Last Four Weeks of the Double-Blind Treatment Period — 17.0; 17.8 percentage of subjects — p=0.9002
N/A N=94 Lcr35 for Children With Functional Constipation
Constipation
Primary: Number of Participants With Treatment Success (≥3 Spontaneous Defecations Per Week With no Fecal Soiling — 24; 28 Participants — p=0.399
Phase 3 N=123 A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
Functional Constipation (FC) · Chronic Idiopathic Constipation (CIC)
Primary: Change From Baseline in 12-week Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) Observed by the Primary Caregiver During the Double-blind Study Intervention…
N/A N=207 Clinical Study to Investigate the Effectiveness of the TOPAS System to Treat Fecal Incontinence
Fecal Incontinence
Primary: Percentage of Responders — 69.1 percentage of treatment responders
N/A N=27 Effects of Exercise Training on Pelvic Floor Symptoms and Function in Adults With Constipation
Constipation
Primary: Severity of Constipation Symptoms — 0.96; 0.97; 0.63; 0.67 score on a scale
N/A N=72 Physiotherapeutic Intervention in Children With Chronic Functional Constipation
Chronic Constipation
Primary: Frequency of Defecation. — 3.9; 5.1 days/week — p=<0.05
Phase 2 N=19 A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide
Functional Constipation
Primary: Change From Baseline in Overall Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) During the Study Intervention Period — 3.181; 2.503; 0.246; 3.371 SBMs/Week
Phase 2 N=124 An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation
Chronic Idiopathic Constipation
Primary: Proportion of Overall Responders — 7; 10; 12; 7 Participants
Phase 2 N=35 Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation
Functional Constipation
Primary: Change From Baseline in 4-week Overall Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) During the Study Intervention Period of Each Cohort — 1.379; 0.621…
N/A N=101 Long Term Efficacy of Sacral Nerve Modulation (SNM) in Patients With Constipation or Stool Incontinence
Constipation · Fecal Incontinence
Primary: Percentage of Patients Considering the Treatment a Success After 5 Years — 81.7; 87.3; 31.2; 91.7 percentage of success
Phase 4 N=153 The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation
Functional Constipation
Primary: Change of Clostridium Butyricum Miyairi Expression After Probiotics Supplementation in Constipated Children. — 0.00486; 0.0000148; 0.00000189 number of bacteria per mg…